Acute Dose-dependent Effects of DMT in Healthy Subjects
Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · May 17, 2022
Trial Information
Current as of June 03, 2025
Completed
Keywords
ClinConnect Summary
N,N-dimethyltryptamine (DMT) is a naturally-occurring psychedelic substance widely used in recreational and spiritual settings (Ayahuasca). DMT is considered a tool to induce an altered state of consciousness of interest in psychological and psychiatric research. DMT is rapidly metabolized by monoamine oxidase (MAO) A. Therefore, it is inactive when administered orally and has a very short duration of action when administered parenterally (\<20 min). In Ayahuasca, DMT is consumed together with harmala alkaloids that inhibit MAO to increase the oral bioavailablitity of DMT and to prolong its...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age between 25 and 65 years old
- • 2. Sufficient understanding of the German language
- • 3. Understanding of procedures and risks associated with the study
- • 4. Willing to adhere to the protocol and signing of the consent form
- • 5. Willing to refrain from the consumption of illicit psychoactive substances during the study
- • 6. Abstaining from xanthine-based liquids from the evenings prior to the study sessions and during the sessions
- • 7. Willing not to operate heavy machinery within 6 h of DMT administration
- • 8. Willing to use double-barrier birth control throughout study participation
- • 9. Body mass index between 18-29 kg/m2
- Exclusion Criteria:
- • 1. Chronic or acute medical condition
- • 2. Current or previous major psychiatric disorder (e.g. psychotic disorders, mania / hypomania, anxiety disorders).
- • 3. Psychotic disorder or bipolar disorder in first-degree relatives
- • 4. Hypertension (SBP\>140/90 mmHg) or hypotension (SBP\<85 mmHg)
- • 5. Hallucinogenic substance use (not including cannabis) more than 20 times or any time within the previous two months
- • 6. Pregnancy or current breastfeeding
- • 7. Participation in another clinical trial (currently or within the last 30 days)
- • 8. Use of medication that may interfere with the effects of the study medication
- • 9. Tobacco smoking (\>10 cigarettes/day)
- • 10. Consumption of alcoholic beverages (\>20 drinks/week)
About University Hospital, Basel, Switzerland
The University Hospital Basel, Switzerland, is a leading academic medical center renowned for its commitment to cutting-edge research and innovative patient care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise and state-of-the-art facilities to advance medical knowledge and therapeutic options across various disciplines. With a collaborative approach that integrates clinical practice and scientific inquiry, the University Hospital Basel fosters an environment conducive to rigorous clinical trials, ensuring the highest standards of safety and efficacy. Its strategic focus on patient-centered research aims to translate scientific discoveries into tangible health solutions, benefiting both local and global communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Basel, , Switzerland
Patients applied
Trial Officials
Matthias E Liechti, MD
Principal Investigator
University Hospital Basel, Basel, Switzerland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials